Drugs / NAL-GLU
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT00386022 Background | Jan 2002 → Jan 2012 | — | Massachusetts General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nal-Glu | “administration of a GnRH antagonist (Nal-Glu at 150 mg/kg that blocks endogenous GnRH” NCT00386022 ↗ |
| Action | Inhibit | “Nal-Glu at 150 mg/kg that blocks endogenous GnRH” NCT00386022 ↗ |
| Route | Subcutaneous | “A single subcutaneous injection” NCT00386022 ↗ |